The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2013Discovery of EEG Biomarkers for Parkinson's Disease and Lewy Body Dementia
Objective/Rationale:
We aim to develop a non-invasive, low-cost pre-clinical biomarker for synucleinopathies such as Parkinson’s disease (PD) or Lewy body dementia (LBD), which will have... -
Research Grant, 2013DPI-289, a Novel Bi-Functional Delta Agonist / Mu Antagonist (DAMA) as a Therapy for Parkinson's Disease
Objective/Rationale:
Eboo Pharmaceuticals Inc. is developing an approach to treating Parkinson’s disease (PD) via a delta agonist/mu antagonist (DAMA) mechanism expected to provide efficacious and well... -
Research Grant, 2013Preferential Targeting of Subpopulations of 5-HT1A Receptors: Microdialysis Study
Promising Outcomes of Original Grant:
Researchers investigated the effects of serotonin 5-HT1A biased agonists on rotation behavior in pre-clinical models. The scientists used a pre-synaptic (before... -
Therapeutic Pipeline Program, 2013Exenatide as a Treatment for Patients with Parkinson’s Disease
Objective/Rationale:
Laboratory data from several teams have indicated potential beneficial effects of the drug Exenatide on the survival of dopamine cells. In a small group of patients... -
Rapid Response Innovation Awards, 2013Effect of Alpha-Synuclein Depletion in Dopamine Neurons of Pre-Clinical Models
Objective/Rationale:
A key event in the development of pathological changes in the nervous system of Parkinson’s disease patients is aggregation of a small synaptic protein: alpha-synuclein. Certain... -
Dyskinesia Challenge, 20135-Hydroxytryptophan and Eltoprazine for the Treatment of Levodopa-Induced Dyskinesia
Objective/Rationale:
The appearance of dyskinesia presents new challenges as a symptom of long-term Parkinson’s therapy with levodopa. Our recent studies have identified the serotonin...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.